01:14 PM EDT, 03/13/2026 (MT Newswires) -- Johnson & Johnson ( JNJ ) said early results from a Phase 1 study of Erda-iDRS, an investigational drug-releasing bladder insert containing erdafitinib, show encouraging signs in patients with intermediate- and high-risk non-muscle invasive bladder cancer with select fibroblast growth factor receptor alterations.

The study met its primary safety goal and produced complete, durable responses in patients with recurrent intermediate-risk disease, along with promising recurrence-free responses in high-risk patients, the company said Friday in a statement. Erda-iDRS is designed to slowly release erdafitinib directly into the bladder over a three-month period.

The findings support continued development of the targeted approach, with Phase 2 and Phase 3 studies underway, the company said.

Price: 243.42, Change: +1.38, Percent Change: +0.57